Virus therapy tested to fight tough cancers
NCT ID NCT06063317
Summary
This early-stage study tested the safety of a new treatment called CF33-CD19, a modified virus designed to attack cancer cells. It was given alone or combined with another immunotherapy drug (blinatumomab) to adults with advanced solid tumors that had stopped responding to at least two prior treatments. The main goal was to find a safe dose and see how the body's immune system reacted, but the study was later terminated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Northwestern
Chicago, Illinois, 60208, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15219, United States
Conditions
Explore the condition pages connected to this study.